姬秋和 教授 附属西内分泌代谢科 主任医师、教授、博士研究生导师
参考文献: [1]Juan P.Frías,et al.Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes .August 5,2021.N Engl J Med 2021;385:503-515.DOI:10.1056/NEJMoa2107519 [2]American Diabetes Association.Introduction:standards of medical care in diabetes-2021.Diabetes Care 2021;44:Suppl 1:S1-S2. [3]Buse JB,Wexler DJ,Tsapas A,et al.2019 update to:Management of hyperglycaemia in type 2 diabetes,2018:a consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD).Diabetologia 2020;63:221-228. [4]Müller TD,Finan B,Bloom SR,et al.Glucagon-like peptide 1(GLP-1).Mol Metab 2019;30:72-130. [5]Pelle MC,et al.Role of a Dual Glucose-Dependent Insulinotropic Peptide(GIP)/Glucagon-like Peptide-1 Receptor Agonist(Twincretin)in Glycemic Control:From Pathophysiology to Treatment.Life(Basel).2021 Dec 25;12(1):29. [6]Samms RJ,Coghlan MP,Sloop KW.How may GIP enhance the therapeutic efficacy of GLP-1 Trends Endocrinol Metab 2020;31:410-421. [7]Coskun T,Sloop KW,Loghin C,et al.LY3298176,a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus:from discovery to clinical proof of concept.Mol Metab 2018;18:3-14. [8]Zhang Q,Delessa CT,Augustin R,et al.The glucose-dependent insulinotropic polypeptide(GIP)regulates body weight and food intake via CNS-GIPR signaling.Cell Metab 2021;33(4):833.e5-844.e5. [9]Christensen M,Vedtofte L,Holst JJ,Vilsb ll T,Knop FK.Glucose-dependent insulinotropic polypeptide:a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.Diabetes 2011;60:3103-3109. |
|
来自: 尚振奇 > 《GLP1、GIP受体激动剂》